Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04528355 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC

Study acronym: PRO-RIC
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2027
    • Study completion date: Jun 30, 2026 to Jun 30, 2028
    • Site contact updated
    v8
  2. Site contact updatedv7
  3. 4 versions Re-verified since Sep 17, 2021, no change to tracked fieldsv3-v6
  4. Secondary endpoints: details revised at 4 of 4 entriesv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Paul Szabolcs
9 trials monitored
See 2 trials at risk
Rheumatoid Arthritis
661 trials monitored
See 14 trials at risk
Crohn's Disease
642 trials monitored
See 34 trials at risk
Sickle Cell Disease
373 trials monitored
See 23 trials at risk
and 1 more disease
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen paired with simple alemtuzumab dosing strata designed to prevented graft failure and to aid in immune reconstitution following hematopoietic stem cell transplantation.
Trial Details
NCT Number NCT04528355
Lead Sponsor Paul Szabolcs
Conditions
(from sponsor)		 Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions
Related terms Adrenoleukodystrophy, alpha-Mannosidosis, Anemia, Diamond-Blackfan, Anemia, Sickle Cell, Arthritis, Rheumatoid, Autoimmune Lymphoproliferative Syndrome, beta-Thalassemia, Chediak-Higashi Syndrome, Congenital amegakaryocytic thrombocytopenia, Congenital Bone Marrow Failure Syndromes, Crohn Disease, Gaucher Disease, Granulomatous Disease, Chronic, Hyper-IgM Immunodeficiency Syndrome, Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome, Inflammatory Bowel Diseases, Leukocyte adhesion deficiency type 1, Leukodystrophy, Globoid Cell, Leukodystrophy, Metachromatic, Lymphohistiocytosis, Hemophagocytic, Mucopolysaccharidosis I, Osteopetrosis, Primary Immunodeficiency Diseases, Severe Combined Immunodeficiency, Sudden Infant Death, Syndrome, Wiskott-Aldrich Syndrome
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov